For SOD1 ALS, several studies have demonstrated the benefits of both active and passive immunotherapy in mutant SOD1 models, although the success of injecting recombinant SOD1 mutant protein to induce immunity seems to be dependent on the SOD1 mutation. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.